In Pink Sheet, Katherine Wang Examines China’s Drug Regulatory Agency Reorganization
Life sciences partner Katherine Wang (Shanghai) was quoted in a Pink Sheet article on Mar. 14 that discusses the impact of a new proposal by China’s State Council to reduce the number of state agencies overseeing drug regulation.
The plan would merge the nation’s top drug regulator, China FDA, into a new combined body called the National Regulatory and Management Commission, and create a medical reimbursement agency to oversee China’s health insurance policy-making, in a move designed to strengthen regulatory oversight.
Ms. Wang explains that the proposal is potentially a separation of pre-market and post-market functions into two agencies. The impact to the China drug industry could be different standards in enforcing the regulations.